The effect of chlorpromazine in dosages considerably higher than normally used in psychiatric practice, was investigated on patients in a mental hospital. Reports of similar studies in this field have been published'>". The group consisted of 53 female patients, 43 were chronic schizophrenics and 10 were in different diagnostic categories. Results concerning the latter group are not reported herewith.
The treatment began with 200 mgs chlorpromazine daily, given in 4 doses. This was increased weekly by 200 mgs and, barring dangerous complications, was continued until 2,000-3,000 mgs per day was reached. The tolerance of the patient dictated the dosage. The group was kept on this high dosage for 5-8 months.
Each patient underwent an examination before chlorpromazine therapy was instituted. This consisted of daily charting of blood pressure, temperature and pulse; weekly blood cell counts and urine analysis for bile and urobilinogen; monthly series of liver tests. As well as seeing the patients on the regular ward rounds, special interviews were held individually on a weekly basis for the first two months, and thereafter once a month until the end of treatment. Patients were not restricted in their ordinary routine.
In 8 months the largest total dosage was 429,000 mgs, the patient who received this had a daily dosage of 3,000 mgs. The smallest amount taken by an individual during the 5 month course was 68,000 mgs, the highest daily dose of this patient was 1,200 mgs. Most of the patients were getting small doses of chlorpromazine before this study began.
In the schizophrenic group the average age was 39.5 years. The youngest patient was 14 years old, the eldest 57. The average length of hospitalization of the group was 10.4 years, the shortest being 2 years and the longest 30. Table I shows 20.9% of our patients were classified as "Remissions" and 39.5% as "Social Remissions", which made a total of 60.4% who could be discharged. It is customary to evaluate the outcome of treatment in studies similar to this one in terms of duration of illness. The meaning of such a procedure, however, is restricted. Among a group of patients who have spent approximately the same number of years institutionalized, there are differences in the severity of illness which may be measured, in one way by the level of deterioration. Consequently, it was decided to rate the patients using an index of deterioration rather than relying on comparisons made in conjunction with length of hospitalization. Arieti's system was used for this purpose'. A brief description of different stages in schizophrenia is as follows:
The first phase of schizophrenia is characterized by anxiety or depressive mood, deeply affective delusions and hallucinations.
In the second or advanced stage anxiety diminishes or disappears, hallucinations and delusions become stereotyped, do not effect the activity of the patient. Thinking is more disconnected.
In the third or preterminal stage the patient's hallucinations or delusions become disorganized and lose emotional value. Thought content disintegrates, new habits like picking the skin, pulling out hair, rhythmic movements, hoarding and self decorating set in. 'In the fourth or terminal stage there is no evidence of hallucinations or delusions. Speech is restricted to a few jumbled phrases. Food grabbing (tachyphagia), and swallowing of inedible substances (koprophagia) occurs. The patient appears insensitive to many stimuli, temperature, pain and taste. In our patients there was a 50% remission among those who were not deteriorated. The remission rate fell to 20% in the group with second grade deterioration. There was no remission among those classified in the third grade nor did the one patient in the terminal stage change with treatment.
. It is interesting to note that almost 60% of those in the second grade of deterioration became well enough to be considered socially recovered. Among the patients in the third grade of deterioration 20% were in the "Social Remission" category, and 40% were in the "Improved" category. Analysing our results according to the schizophrenic sub-groups, we found remissions occurred only in the Paranoid group. There were no complete remissions among the Simple schizophrenic, but there were good social remissions. There were only 2 patients in the Hebephrenic sub-group. Both patients remained unchanged.
In one group the treatment produced a somewhat opposite effect to the one desired, i.e. the patients became greatly excited and could not sleep. However, after discontinuation of the treatment they were improved and were released. Consequently it has been our experience that the exacerbation of symptoms does not preclude the continuation of the chlorpromazine course. The hereditary background of the group was strongly loaded and their premorbid personalities, almost without exception, could be described as schizoid. Yet, we were able to discharge 16 patients, or 37.2%; 7 from the "Remitted Group", 8 from the "Socially Remitted", and 1 from the "Improved Group". Another 9 patients were suitable for discharge but had to remain hospitalized for administrative reasons. This would bring the total dischargeable to 60.4%, or 9 in the "Remitted Group", 15 in the "Socially Remitted" and 1 in the "Improved Group".
Laboratory Tests
There is little agreement concerning the effects of chlorpromazine on liver chemistry. While some authors have reported that when using routine liver function tests they were unable to detect any abnormality", others such as Deutsch found mal-functioning livers in a little less than 50% of his patients", In all cases, after three to four months, the urine bile became positive and remained so for one to two months after discontinuation of treatment. The urobilinogen test became positive later, after bile was found in the urine, and remained positive to the end of the second or third month after discontinuation of treatment. There appeared to be a direct relationship between increased dosage and increased bilirubin, this was especially true in the case of the direct bilirubin. However, it became higher than 1 mg. in 2 cases only. In the cases where the direct bilirubin or total bilirubin was greater than 1 mg. the daily dosage was higher than 1,000 mgs. of chlorpromazine.
Thymol Turbidity and Cephaline Cholesterol Flocculation (CCF) tests were performed on all patients before treatment and during treatment with monthly intervals. 66% of all the CCF tests were positive before treatment, 41% of them were more than 2 plus. By the end of the treatment 57.6% of the positive CCF tests had become negative and in only 3 cases was this tendency reversed. 33% of the CCF tests were positive at the end of treatment, in comparison to the 66% positive before treatment.
To illustrate the improvement found in some liver function tests, the case of a patient who was given 194,900 mgs. chlorpromazine over 6 months of treatment is used as an example. Her Thymol Turbidity Test was 4 units prior to treatment. It progressively decreased month by month from 4 to 5.0, 3.5, 3.0,2 finally reaching zero in the last testing. Her CCF test was 3 plus before treatment. Through the treatment it went from 2 plus, 2 plus, one plus to negative. There were cases where decrease was not so gradual, the liver function tests became negative suddenly and stayed negative for the duration of treatment. Three months after treatment was discontinued the liver condition of 20 patients was checked with a battery of tests, including total protein, alkaline phosphatase, A/G ration, Bromsulphtaleine, and Takata Ara. With the exception of one slightly positive Bromsulphtaleine test, all the tests were negative.
Comparing the results of the CCF test with clinical observation of patients involved, we found that of those whose liver function tests became negative or improved as well as those whose liver function tests showed no change from the original negative results, 85% were classified "Remitted" or "Socially Remitted". 5% of these patients were not considered improved. On the other hand, of those whose liver tests were positive before treatment and remained positive, or those whose liver tests became worse, only 33% were classified as "Remitted" or "Socially Remitted", 40% as compared to 5% of the above group were considered as failures.
Four months after treatment was discontinued CCF tests were repeated on some of the patients. In this rough spot-check we found two cases in which the symptomatological improvement was only temporary. The CCF tests of these patients, which had become negative during treatment, again became positive with exactly the same value as before the treatment was started. It would be tempting to think along the same lines as those who have proposed a hepatotoxic theory of schizophrenia; (Platania, De La Vega, De J ong (2». One cannot, of course, ignore the possibility that the liver abnormality is not the cause but the result of the schizophrenic conditions, brought about either directly by a change in the nervous system, or indirectly by the environmental conditions of the hospitalized patient which include, among other things, faulty eating habits, or unsatisfactory diet.
Although we do not pretend to answer this question on the basis of our study, we think that the role of the CCF test should be given greater consideration as a means of predicting the outcome of chlorpromazine treatment.
There was one case of Jaundice, which occurred during the first month of treatment at a dose of 600 mgs. daily. This was probably due to individual sensitivity. Summary 1. Chlorpromazine treatment was carried out with 53 female patients, 43 of whom were chronic schizophrenics. The dosage was high, up to 3,000 mgs. daily and the treatment lengthy, from six to eight months.
2. Among the chronic schizophrenic, remission occurred in 20% and Social Remission in 37% of the cases. Length of illness and grades of deterioration bear an inverse relationship to improvement.
3. Both paranoid and simplex schizophrenic patients benefitted from the treatment.
4. No permanent liver damage occurred. A large percentage of the previously positive CCF tests improved during the treatment and this was paralleled by psychological improvement. 
REPORT ON HOSPITAL AND MEDICAL INSURANCE PLANSS
ince 1954 the Committee on Psychiatric Coverage in Hospital and Medical Insurance Plans has been following with interest the gradual improvement in the way in which the professionally sponsored prepaid medical care plans have provided insurance against the cost of the medical care of psychiatric disorders.
The summary of policies and practices of these plans as contained in this report is correct to September 1960. The committee feels that a comparison between this report and the first report prepared in 1954 shows encouraging progress. A summary of current hospital insurance practices concerning psychiatric illness will be reported at a later date. J. D. Griffin, M.D. 
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